What Is Nitroxoline Prescription Information?

Nitroxoline Prescription Information matters because this older urinary antiseptic is not regulated or marketed identically worldwide. In some countries, clinicians prescribe nitroxoline for selected uncomplicated urinary tract infections. Elsewhere, it may have no current marketing authorization. That difference can change the product label, dosage instructions, age limits, and refill rules.

The World Health Organization’s 2023 Antibacterial Agents in Clinical and Preclinical Development report warns that the antibiotic pipeline remains insufficient against rising resistance. WHO also reports that antimicrobial resistance threatens routine medical care. As WHO Director-General Dr. Tedros Adhanom Ghebreyesus stated, “Antimicrobial resistance is one of the greatest threats to global health, food security and development today.” This warning gives nitroxoline renewed research interest, but it does not replace clinical evidence or local prescribing rules.

Reliable Nitroxoline Prescription Information should explain the approved indication, strength, administration schedule, treatment duration, contraindications, and important interactions. It should also clarify whether urine culture testing is appropriate. A prescription label is not a diagnosis. Kidney function, pregnancy status, allergy history, age, and infection severity can change the safest choice. Even small details matter, such as taking tablets with water and reporting persistent fever or flank pain promptly. Evidence remains uneven across regions and patient groups. That limitation deserves attention, not polished overconfidence. Readers should verify every recommendation against a licensed clinician, current national labeling, and reputable antimicrobial guidance.

Table of Contents [Hide]

1 Nitroxoline Prescription Status: ATC Code J01XX07 and Regional Authorization

2 Clinical Uses: Uncomplicated UTIs and Culture-Based Pathogen Selection

3 Prescription Dosing: Label-Specific 250 mg Regimens and Renal Review

4 Safety Profile: Contraindications, Interactions, and Reported Adverse Events

5 Treatment Monitoring: Urine Cultures, EUCAST Data, and Stewardship Criteria

Nitroxoline Prescription Status: ATC Code J01XX07 and Regional Authorization

Nitroxoline prescription information begins with its classification. The WHO Collaborating Centre’s ATC/DDD Index assigns nitroxoline the code J01XX07. This code places it among other antibacterials for systemic use. It does not confirm approval, supply, or prescription rules in every country. Those decisions belong to national medicines regulators.

Regional authorization must be checked separately. A country may list nitroxoline as prescription-only, restrict it to specific urinary infections, or omit it from the active market. Approved labels can differ on age limits, renal function warnings, dosing, and treatment duration. A pharmacist or physician should verify the current national product information before prescribing. Old online references can mislead.

The WHO AWaRe 2023 report uses a 70% Access-antibiotic benchmark for national consumption. That benchmark supports stewardship, but it does not establish nitroxoline’s clinical role. Local resistance data, diagnostic testing, and prescribing guidance remain more useful. OECD antibiotic-consumption reporting also shows major variation between countries, often measured as defined daily doses per 1,000 people per day. Nitroxoline may not be included consistently, especially where surveillance is incomplete. That is an important limitation. Prescription status should therefore be confirmed through the regulator’s database, the latest official label, and local antimicrobial guidance. Classification is not authorization. Neither is availability.

Clinical Uses: Uncomplicated UTIs and Culture-Based Pathogen Selection

What Is Nitroxoline Prescription Information?

Nitroxoline may be prescribed for selected uncomplicated lower urinary tract infections, depending on national approval and local guidelines. It is not suitable for every urinary symptom. The target is usually bacterial cystitis without fever, flank pain, pregnancy-related complexity, or suspected kidney infection. The EAU Guidelines on Urological Infections emphasize accurate diagnosis and responsible antibiotic selection. Nitroxoline should be used only when the suspected pathogen is susceptible.

Culture matters.

Urine culture is especially useful after treatment failure, recurrent infection, atypical symptoms, or recent antibiotic exposure. It can identify organisms such as Escherichia coli and reveal resistance that empirical treatment may miss. The WHO GLASS 2024 report shows continued global antimicrobial resistance surveillance gaps. Local resistance data can therefore be more useful than international averages.

A practical limitation remains: many laboratories do not routinely report nitroxoline susceptibility. That gap deserves attention, not assumption. Prescribers should also review renal and hepatic function, allergies, pregnancy status, and possible interactions. Local authorization differs.

Tips: Provide a clean midstream urine sample before treatment when culture is indicated. Do not use leftover medicine. Seek urgent care for fever, vomiting, flank pain, or worsening symptoms. A slightly unusual point: symptom relief alone does not prove bacterial clearance. Reassessment may be necessary.

Prescription Dosing: Label-Specific 250 mg Regimens and Renal Review

What Is Nitroxoline Prescription Information?

Prescription information for nitroxoline must follow the approved local product label. A 250 mg capsule is not automatically a complete regimen. The label should specify the dose frequency, treatment duration, indication, and administration instructions. Clinicians should confirm the actual formulation before prescribing. Strengths and schedules may differ between countries. They may also differ between urinary infections and other labeled uses.

Renal review is essential before a 250 mg regimen begins. Check recent serum creatinine, estimated kidney function, urine output, and relevant medical history. Ask about chronic kidney disease, dehydration, dialysis, or previous urinary obstruction. Do not assume a normal result from several months ago remains reliable. A patient with vomiting or poor fluid intake may need reassessment today. The clinician or pharmacist should verify whether the label allows treatment at the patient’s renal function level. Dose reduction, avoidance, or closer monitoring may be appropriate, depending on local guidance. Patients should not split doses, extend therapy, or restart leftover medicine without professional advice. One detail is easy to miss: persistent fever, flank pain, or worsening symptoms can indicate a more serious infection. That situation needs prompt medical review. Prescription decisions should be documented clearly, including the renal value used and the reason for the selected 250 mg schedule. My own caution is simple: a convenient strength can create false confidence. Availability does not prove suitability.

Safety Profile: Contraindications, Interactions, and Reported Adverse Events

What Is Nitroxoline Prescription Information?

Nitroxoline prescription decisions require patient-specific safety screening. Official product information lists hypersensitivity as a key contraindication. Severe kidney impairment also requires caution or avoidance, depending on local labeling. Liver disease, pregnancy, and breastfeeding need medical review. Evidence is not perfectly consistent across countries.

Reported adverse events usually include nausea, stomach discomfort, headache, rash, and temporary yellow-orange urine. Severe allergic reactions appear uncommon, but they require urgent care. WHO VigiBase pharmacovigilance data show that spontaneous reports can identify rare reactions, yet they cannot prove causation or calculate true incidence. This limitation matters. Underreporting remains possible.

Tips: Tell the prescriber about kidney disease, liver problems, allergies, pregnancy, and all supplements. Separate mineral supplements or antacids only when a clinician advises it, because absorption interactions may occur. Do not combine urinary medicines casually. Check the local leaflet, since contraindications and dosing thresholds may differ. Clinical monitoring is sensible when symptoms worsen, urine output falls, or a rash develops. The evidence base still needs stronger comparative safety studies.

What Is Nitroxoline Prescription Information? - Safety Profile: Contraindications, Interactions, and Reported Adverse Events

Safety Dimension	Information	Clinical Relevance	Risk Level	Recommended Action
Therapeutic use	Nitroxoline is an antibacterial urinary antiseptic used in some countries for susceptible urinary tract infections.	Use should be based on the suspected or confirmed pathogen, local prescribing information, and antimicrobial susceptibility where available.	Use is indication-specific	Follow the applicable local prescription label and clinical guidance.
Hypersensitivity	Contraindicated in patients with a known allergy or serious previous reaction to nitroxoline or related 8-hydroxyquinoline compounds.	Prior drug allergy may increase the risk of rash, angioedema, bronchospasm, or anaphylaxis.	High if re-exposed	Avoid use when a relevant hypersensitivity history is present; seek urgent care for breathing difficulty or facial swelling.
Renal impairment	Severe renal dysfunction is commonly listed as a contraindication or precaution in regional product information.	Reduced renal function may alter exposure and can make urinary treatment less appropriate or less predictable.	Potentially significant	Review renal function before prescribing; avoid or adjust only according to local labeling and specialist advice.
Hepatic impairment	Severe liver disease is listed as a contraindication or major precaution in some national prescribing information.	Pre-existing liver disease may increase concern about abnormal liver tests or impaired drug handling.	Potentially significant	Assess liver history and consider liver-function testing when clinically appropriate.
Pregnancy	Safety data in pregnancy are limited, and use may be restricted or discouraged depending on the jurisdiction.	Insufficient human evidence makes routine use inappropriate unless the expected benefit clearly outweighs potential risk.	Limited evidence	Consult the current local label and a qualified clinician before use.
Breastfeeding	Information on transfer into human milk and effects on breastfed infants is limited.	The potential for infant exposure should be considered when treatment is being evaluated.	Limited evidence	Seek individualized medical advice before treatment during lactation.
Antacids and mineral-containing products	Products containing polyvalent cations, such as magnesium or aluminum, may reduce absorption of some quinoline-related medicines; product-specific evidence for nitroxoline may vary.	Reduced absorption could lower urinary exposure and compromise treatment effectiveness.	Possible interaction	Check the local prescribing information and separate administration only if specifically recommended.
Other medicines	Comprehensive interaction data are limited compared with extensively studied systemic antibiotics.	Absence of a documented interaction does not prove that an interaction cannot occur.	Uncertainty present	Provide the prescriber or pharmacist with a complete medication and supplement list.
Gastrointestinal effects	Nausea, vomiting, abdominal discomfort, diarrhea, or reduced appetite have been reported with nitroxoline therapy.	Symptoms are generally mild but may affect adherence or contribute to dehydration.	Usually mild	Take only as directed; contact a clinician if symptoms are severe, persistent, or accompanied by dehydration.
Neurologic effects	Headache, dizziness, or other neurologic symptoms have been reported. Rare neurologic toxicity has been described with some 8-hydroxyquinoline derivatives.	New numbness, tingling, weakness, confusion, or balance problems require medical assessment.	Uncommon but important	Stop and seek medical advice promptly if significant neurologic symptoms develop.
Skin and allergic reactions	Rash, itching, and other hypersensitivity reactions may occur; severe cutaneous reactions are considered rare but medically important.	Blistering, mucosal sores, skin peeling, fever, or facial swelling may indicate a serious reaction.	Rare but potentially serious	Discontinue and obtain urgent medical evaluation for severe or rapidly progressing symptoms.
Urine discoloration	Yellow, orange, or dark discoloration of urine may occur because of the drug or its metabolites.	This effect is generally benign and may be mistaken for blood in the urine or dehydration.	Usually harmless	Inform the patient in advance; seek advice if discoloration is accompanied by pain, blood, or jaundice.
Liver-related events	Elevated liver enzymes and other liver-related adverse events have been reported, although frequency may vary across sources.	Risk may be more relevant in people with pre-existing liver disease or symptoms suggestive of hepatic injury.	Monitor when indicated	Report jaundice, dark urine, severe fatigue, or persistent right-upper-abdominal pain promptly.
Blood-related events	Rare blood-count abnormalities may be reported in post-marketing or clinical safety information.	Unexplained bruising, recurrent infection, fever, or unusual fatigue may require investigation.	Rare but important	Seek clinical assessment if concerning symptoms occur; laboratory testing should be guided by the clinician.
Treatment monitoring	Routine laboratory monitoring is not required for every patient, but renal and hepatic assessment may be appropriate for patients with relevant medical conditions or prolonged treatment.	Monitoring supports safer use when organ impairment, advanced age, multiple medicines, or persistent symptoms are present.	Patient-dependent	Use individualized monitoring based on the current prescription information and clinical judgment.
Treatment response	Failure to improve, worsening urinary symptoms, fever, flank pain, or systemic illness may indicate resistant infection or a complicated urinary infection.	Nitroxoline may not be appropriate for severe or upper-tract infection requiring different management.	Requires reassessment	Contact a healthcare professional promptly; urgent evaluation is warranted for systemic symptoms or flank pain.

Safety information and contraindications can differ between countries and formulations. This table is for general prescription-information reference and does not replace the current official labeling or advice from a qualified healthcare professional.

Treatment Monitoring: Urine Cultures, EUCAST Data, and Stewardship Criteria

What Is Nitroxoline Prescription Information?

Treatment Monitoring: Urine Cultures, EUCAST Data, and Stewardship Criteria

Nitroxoline prescription information should connect the medicine with a confirmed urinary infection. A urine culture helps identify the organism before treatment, especially with recurrent symptoms, pregnancy, complicated infections, or recent antibiotic exposure. Urinalysis can support assessment, but it cannot replace culture results in higher-risk cases. Clinicians should review allergy history, kidney and liver status, symptom severity, and possible drug interactions. A positive culture alone is not always an infection. Contamination and asymptomatic bacteriuria can lead to unnecessary treatment.

EUCAST data should guide susceptibility interpretation when applicable. Clinicians must check the current EUCAST breakpoint tables, testing methods, and organism-specific guidance. If no validated breakpoint exists, the result needs cautious interpretation. Local laboratory policies and resistance patterns also matter. Monitoring should include symptom response, fever, flank pain, and new systemic signs. Persistent symptoms may require repeat culture and reassessment for obstruction, another diagnosis, or a resistant organism. Stewardship means using nitroxoline only when the clinical indication is clear, the likely pathogen is susceptible, and the expected benefit outweighs harm. Real-world decisions are not always tidy.

Tips: Collect urine before therapy when practical. Use a clean-catch sample. Document recent antibiotics. Do not extend treatment without review. Reconsider therapy if cultures conflict with symptoms. A brief follow-up call can reveal worsening pain or fever earlier than a scheduled visit.